Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - erysipelothrix rhusiopathiae; leptospira interrogans serovar pomona; porcine parvo virus; formaldehyde; thiomersal - parenteral liquid/solution/suspension - erysipelothrix rhusiopathiae vaccine-general active 0.0 u; leptospira interrogans serovar pomona vaccine-microbial active 0.0 u; porcine parvo virus vaccine-viral active 0.0 u; formaldehyde aldehyde other 0.3 mg/ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - erysipelas - swine | leptospirosis - leptospira pomona | parvovirus | vaccine | equine rotavirus | l. interrogans serovar pomona | leptospira pomona infection | swine erysipelas

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - erysipelothrix rhusiopathiae; leptospira interrogans serovar pomona; formaldehyde; thiomersal - misc. vaccines or anti sera - erysipelothrix rhusiopathiae vaccine-general active 0.0 p; leptospira interrogans serovar pomona vaccine-microbial active 0.0 p; formaldehyde aldehyde other 1.2 mg/ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - erysipelas infection | leptospirosis - leptospira pomona | l. interrogans serovar pomona | leptospira pomona infection

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - erysipelothrix rhusiopathiae; whole cell e. coli including fimbrial antigens k88, k99; leptospira interrogans serovar pomona; formaldehyde; thiomersal - misc. vaccines or anti sera - erysipelothrix rhusiopathiae vaccine-general active 0.0 u; whole cell e. coli including fimbrial antigens k88, k99 vaccine-microbial active 0.0 u; leptospira interrogans serovar pomona vaccine-microbial active 0.0 u; formaldehyde aldehyde other 0.3 mg/ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - pig - piglet | pigs | boar | gilt | neonatal piglet | new born pig | piglet | sow | sucker pig | swine - erysipelas infection | escherichia coli scours | leptospirosis - leptospira pomona | l. interrogans serovar pomona | leptospira pomona infection | white scours

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 400 mg (equivalent: moxifloxacin hydrochloride, qty 436.8 mg) - tablet, film coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; hypromellose; ferric oxide; croscarmellose sodium; lactose monohydrate; magnesium stearate; macrogol 400 - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - moxifloxacin hydrochloride monohydrate, quantity: 436.33 mg (equivalent: moxifloxacin, qty mg) - tablet, film coated - excipient ingredients: lactose; povidone; lactose monohydrate; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - moxifloxacin apo (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions:,- acute bacterial sinusitis,- community acquired pneumonia,- acute exacerbations of chronic bronchitis,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin apo may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.,consideration should be given to available official guidance on the appropriate use of antibacterial agents.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - erysipelothrix rhusiopathiae; e. coli strain - o20:k88; e. coli strain - o149:k88; e. coli strain - o64:k99; e. coli strain - o9:987p; porcine parvo virus; formaldehyde; thiomersal - parenteral liquid/solution/suspension - erysipelothrix rhusiopathiae vaccine-general active 0.0 u; e. coli strain - o20:k88 vaccine-microbial active 0.0 u; e. coli strain - o149:k88 vaccine-microbial active 0.0 u; e. coli strain - o64:k99 vaccine-microbial active 0.0 u; e. coli strain - o9:987p vaccine-microbial active 0.0 u; porcine parvo virus vaccine-viral active 0.0 u; formaldehyde aldehyde other 1.2 mg/ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - pig - piglet | pigs | boar | gilt | neonatal piglet | new born pig | piglet | sow | sucker pig | swine - erysipelas infection | escherichia coli scours | leptospirosis - leptospira pomona | parvovirus | l. interrogans serovar pomona | leptospira pomona infection | white scours

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - erysipelothrix rhusiopathiae - 3050 - unknown - erysipelothrix rhusiopathiae - 3050 vaccine active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clarithromycin, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; croscarmellose sodium; macrogol 4000; hypromellose; titanium dioxide; microcrystalline cellulose; powdered cellulose - clarithromycin sandoz clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negat

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: titanium dioxide; powdered cellulose; magnesium stearate; hypromellose; macrogol 4000; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate - clarithromycin sandoz clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negat

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: titanium dioxide; powdered cellulose; magnesium stearate; hypromellose; macrogol 4000; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate - noumed clarithromycin clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negat